Perspective Therapeutics Inc. (CATX) Live Share Price, Invest From India

Perspective Therapeutics Inc. Stock Performance

as on February 5, 2026 at 10:44 pm IST

Day's Low
Day's High
$4.70
Day's Price Range
$5.39
$4.92
4.47%
Downside
9.55%
Upside
52 Week's Low
52 Week's High
$1.60
52-Week Price Range
$6.16
$4.92
67.48%
Downside
25.20%
Upside

Perspective Therapeutics Inc. share price movements today

Previous Close: $5.10
Open: $4.97
Volume: 1.9M
Day's Low - High: $4.70 - $5.39
52 Week Low - High: $1.60 - $6.16

Perspective Therapeutics Inc. Historical Returns

1 Month Return: + 86.81 %
3 Month Return: + 118.88 %
1 Year Return: + 44.07 %
3 Year Return: 0 %
5 Year Return: 0 %

Perspective Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Perspective Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$192.5M

EPS (TTM)

-1.2127

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-91.7M

Revenue (TTM)

1.1M

Profit Margin

0.00%

Return On Equity TTM

-37.26%

Perspective Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Perspective Therapeutics Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Perspective Therapeutics Inc.	BUY	$192.5M	NA	NA	0.00%
Boston Scientific Corp.	BUY	$138.7B	93.79%	50.03	14.43%
Stryker Corporation	BUY	$136.5B	51.04%	46.97	12.07%
Medtronic Plc	BUY	$129.1B	-13.99%	27.28	13.71%
Edwards Lifesciences Corp.	BUY	$49.1B	-6.26%	36.83	23.25%

See all

Stock Returns calculator for Perspective Therapeutics Inc. Stock including INR - Dollar returns

The Perspective Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Perspective Therapeutics Inc. investment value today

Current value as on today

₹1,42,351

Returns

₹42,351

(+42.35%)

Returns from Perspective Therapeutics Inc. Stock

₹38,983 (+38.98%)

Dollar Returns*

₹3,368 (+3.37%)

Analyst Recommendation on Perspective Therapeutics Inc. Stock

Based on 8 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 8 analysts, 87.5% of analysts recommend a 'BUY' rating for Perspective Therapeutics Inc.. Average target price of $12.85

Perspective Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Perspective Therapeutics Inc..

What analysts predicted

61.71%UPSIDE

Target Price

$12.85

Current Price

$4.92

Analyzed by

8 Analysts

Target

$12.85

Perspective Therapeutics Inc. target price $12.85, a slight upside of 61.71% compared to current price of $4.92. According to 8 analysts rating.

Perspective Therapeutics Inc. Stock’s Investor Sentiment and Interest

Investment in Perspective Therapeutics Inc. Shares on INDmoney has grown by 841.66% over the past 30 days, indicating increased transactional activity.

Time period: January 6, 2026 to February 5, 2026

Change:841.66% versus previous 30 day period

Search interest for Perspective Therapeutics Inc. Stock has increased by 450% in the last 30 days, reflecting an upward trend in search activity.

Time period: January 6, 2026 to February 5, 2026

Change:450% versus previous 30 day period

Perspective Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Total Revenue	1	1	0	-	-	-	-	0	0	0
Gross Profit	0	0	0	-	-	-	-	0	0	0
Operating Income	-11	-10	-7	-13	-14	-18	-44	-21	-24	-27
EBITDA	-11	-9	-8	-11	-10	-14	-41	-17	-21	-25
Interest Expense	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-11	-10	-8	-11	-11	-15	-42	-18	-21	-25
Income Tax Expense	0	0	7	-	0	-	-2	-	-2	-
Net Income	-11	-10	-24	-12	-11	-15	-40	-18	-21	-25
Net Profit Margin	-740.40%	-542.48%	-7321.96%	0.00%	0.00%	0.00%	0.00%	-5314.91%	-7408.62%	-12425.36%

Perspective Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Jun 2020	Dec 2020	Jun 2021	Dec 2021	Jun 2022	Dec 2022	Jun 2023	Dec 2023	Dec 2024
Total Revenue	9	9	10	10	10	10	7	7	1	-
Gross Profit	5	5	5	5	4	4	1	1	1	-
Operating Income	-3	-3	-3	-3	-7	-7	-15	-15	-40	10
EBITDA	-3	-3	-3	-3	-	-7	-14	-14	-39	10
Interest Expense	-	0	-	0	-	0	0	-	0	0
Depreciation	0	0	0	0	0	0	-	-	0	2
Income Before Tax	-3	-3	-3	-3	-7	-7	-14	-14	-40	-81
Income Tax Expense	0	0	0	0	-	0	0	-	-2	-2
Net Income	-3	-3	-3	-3	-7	-7	-14	-14	-46	-79
Net Profit Margin	-33.77%	-33.77%	-31.71%	-31.71%	-67.36%	-66.26%	-206.50%	-206.50%	-3243.24%	0.00%

Perspective Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Net Income	-10	-24	-12	-11	-15	-40	-18	6	-25
Operating Cash Flow	-10	-9	13	-8	3	-26	-21	-19	-16
Investing Cash Flow	0	0	-47	-3	-29	-138	-5	4	13
Financing Cash Flow	0	0	166	122	0	0	9	0	0
Change in Cash	-10	-8	142	109	-25	-164	-17	-15	-2

Perspective Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

	Jun 2020	Dec 2020	Jun 2021	Dec 2021	Jun 2022	Dec 2022	Jun 2023	Dec 2023	Dec 2024
Net Income	-3	-3	-3	-7	-7	-14	-14	-46	-79
Operating Cash Flow	-3	-2	-2	-7	-7	-12	-12	-36	-18
Investing Cash Flow	0	0	0	-	0	-57	-	24	-218
Financing Cash Flow	0	64	64	0	0	0	0	0	289
Change in Cash	-2	61	61	-7	-7	0	0	-46	52

Insights on Perspective Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, CATX has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Price Rise
In the last 1 month, CATX stock has moved up by 86.8%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 3 quarters, -18.17M → -25.96M (in $), with an average decrease of 19.5% per quarter
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 3 quarters, 342.0K → 209.0K (in $), with an average decrease of 21.6% per quarter

About Perspective Therapeutics Inc.

the introduction of cesium-131 represents the culmination of decades of work and millions of dollars of investment. top medical centers, hospitals and clinics across the united states are now offering this breakthrough treatment for cancer patients. the word brachytherapy derives from the greek prefix brachy, meaning “short” or “close,” because the titanium capsules containing the radioisotope are implanted directly into the cancerous prostate gland. treatment of cancer using low dose radiation or “seed” brachytherapy was pioneered in the 1960’s as an effective alternative to radical prostatectomy. pioneers in brachytherapy research initially theorized about the use of cesium-131 in a titanium capsule, however scientific and economic limitations at the time prevented its development and iodine-125 emerged as an alternative. beginning in 1967, iodine-125 became the first radioisotope manufactured in a titanium capsule, or seed. while its use continues to this day, many patients and doct

Organisation	Perspective Therapeutics Inc.
Headquarters	2401 Elliott Avenue, Seattle, WA, United States, 98121
CEO	Mr. Johan M. Spoor
E-voting on shares	Click here to vote

Key Management of Perspective Therapeutics Inc.

Name	Title
Mr. Joel David Sendek	Chief Financial Officer
Mr. Shane Cobb	Executive Vice President of Operations
Ms. Annie J. Cheng	Vice President of Investor Relations
Mr. Chris Nenno	General Counsel & Corporate Secretary
Mr. Johan M. Spoor	CEO & Director
Mr. Jonathan R. Hunt	Chief Accounting Officer
Mr. Andrew Bright	Executive Vice President of Brachytherapy
Mr. Amos Hedt BA, PGradDip	Chief Business Strategy Officer
Dr. Markus Puhlmann M.B.A., M.D.	Chief Medical Officer
Dr. Michael K. Schultz Ph.D.	Chief Science Officer

FAQs

What is Perspective Therapeutics Inc. share price today?

Perspective Therapeutics Inc. share price today is $4.92 as on February 5, 2026 at 10:44 pm IST. Perspective Therapeutics Inc. share today touched a day high of $5.39 and a low of $4.7.

What is the 52 week high and 52 week low for Perspective Therapeutics Inc. share?

Perspective Therapeutics Inc. share touched a 52 week high of $6.16 on January 29, 2026 and a 52 week low of $1.6 on April 9, 2025. Perspective Therapeutics Inc. stock price today i.e. February 5, 2026 at 10:44 pm IST is trending at $4.92,which is 20.13% down from its 52 week high and 207.50% up from its 52 week low.

What is Perspective Therapeutics Inc.'s market capitalisation today?

Perspective Therapeutics Inc. market capitalisation is $0.00T as on February 5, 2026 at 10:44 pm IST.

How to invest in Perspective Therapeutics Inc. Stock (CATX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Perspective Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Perspective Therapeutics Inc. Shares that will get you 0.3049 shares as per Perspective Therapeutics Inc. share price of $4.92 per share as on February 5, 2026 at 10:44 pm IST.

What is the minimum amount required to buy Perspective Therapeutics Inc. Stock (CATX) from India?

Indian investors can start investing in Perspective Therapeutics Inc. (CATX) shares with as little as ₹90.283 or $1 (as of February 5, 2026 at 10:44 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹902.83 in Perspective Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on February 5, 2026 at 10:44 pm IST). Based on Perspective Therapeutics Inc. share’s latest price of $4.92 as on February 5, 2026 at 10:44 pm IST, you will get 2.0325 shares of Perspective Therapeutics Inc.. Learn more about fractional shares .